Table 8.

RVFV vaccines tested in IFNAR^−/− mice.

Vaccine	Antigen	Schedule	Dose/delivery	Challenge post-vax^a	Challenge virus/strain	Challenge dose/route	Efficacy (survival)	Ref.
Plasmid DNA	N, Gn, Gc, NSm	P/B, 2 wk interval	100 μg/IM	15 d	MP-12	2 × 10⁴ PFU/IP	0%	Lorenzo et al. (2010)
	Gn, Gc, NSm	P/B, 2 wk interval	100 μg/IM	15 d	MP-12	2 × 10⁴ PFU/IP	0%	Lorenzo et al. (2010)
	N, Gn, Gc	P/B, 2 wk interval	20–100 μg/IM	15 d	MP-12	2 × 10⁴ PFU/IP	29–57%	Lorenzo et al. (2010)
	Gn, Gc	P/B, 2 wk interval	1–100 μg/IM	15 d	MP-12	2 × 10⁴ PFU/IP	0–100%, full protection achieved at 100 μg dose	(Lorenzo et al., 2010; Boshra et al., 2011)
	N	P/B, 2 wk interval	100 μg/IM	15 d	MP-12	2 × 10⁴ PFU/IP	14–43%	(Lorenzo et al., 2010; Boshra et al., 2011)
	N^#	P/B, 2 wk interval	100 μg/IM	15 d	MP-12	2 × 10⁴ PFU/IP	33%	Boshra et al. (2011)
	N^%	P/B, 2 wk interval	100 μg/IM	15 d	MP-12	2 × 10⁴ PFU/IP	43%	Boshra et al. (2011)
	N^*	P/B, 2 wk interval	100 μg/IM	15 d	MP-12	2 × 10⁴ PFU/IP	71%	Boshra et al. (2011)
	N^&	P/B, 2 wk interval	100 μg/IM	15 d	MP-12	2 × 10⁴ PFU/IP	14%	Boshra et al. (2011)
MVA	Gn^$, Gc^$	P	10⁷ PFU/IP	15 d	RVFV isolate 56/74	1000 PFU/IP	14%	Lopez-Gil et al. (2013)

None of the studies reported use of adjuvant.

All vaccines were based on RVFV MP-12 strain. In all studies, virus challenge was given 15 days post vaccination. Sequence was modified by addition of:

^#,

3 tandem repetitions of the C3d gene joined by short linker sequences to the antigen N-terminus;

^%,

CD154 and a flexible linker to the antigen N-terminus;

^*,

ubiquitin to the antigen N-terminus;

^&,

20 amino acid from the C-terminal tail of LIMPII to the antigen C-terminus; or

^$,

tPA signal peptide and C-terminal V5 tag. B, boost; IM, intramuscular; IP, intraperitoneal; MVA, modified Vaccinia Ankara; P, prime; PFU, plaque-forming units.

Refers to time since last vaccine dose administered.